12:00 AM
 | 
Aug 20, 2012
 |  BC Week In Review  |  Company News  |  Other News

AmorChem, Institut de Recherches Cliniques de Montreal (IRCM), National Research Council of Canada, Universite de Montreal endocrine/metabolic news

Life science VC fund AmorChem licensed rights to IP co-owned by the council and the university's Univalor commercialization arm relating to single domain antibody technology. AmorChem, along with IRCM, will use the...

Read the full 136 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >